These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 22184057)

  • 21. Effects of mineralocorticoid receptor blockade on glucocorticoid-induced renal injury in adrenalectomized rats.
    Rafiq K; Nakano D; Ihara G; Hitomi H; Fujisawa Y; Ohashi N; Kobori H; Nagai Y; Kiyomoto H; Kohno M; Nishiyama A
    J Hypertens; 2011 Feb; 29(2):290-8. PubMed ID: 21243738
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Interactions between aldosterone and connective tissue growth factor in vascular and renal damage in spontaneously hypertensive rats.
    de las Heras N; Ruiz-Ortega M; Miana M; Rupérez M; Sanz-Rosa D; Aragoncillo P; Mezzano S; Cachofeiro V; Egido J; Lahera V
    J Hypertens; 2007 Mar; 25(3):629-38. PubMed ID: 17278980
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mineralocorticoid Receptor Blockade Improves Insulin Sensitivity in the Rat Heart and a Possible Molecular Mechanism.
    Wang M; Li Y; Zhou K; Zhang G; Wang Y; Liu T; Zhang Y; Guo A; An Y
    Cell Physiol Biochem; 2016; 39(3):860-70. PubMed ID: 27497962
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mineralocorticoid receptor blockade inhibits accelerated atherosclerosis induced by a low sodium diet in apolipoprotein E-deficient mice.
    Raz-Pasteur A; Gamliel-Lazarovich A; Gantman A; Coleman R; Keidar S
    J Renin Angiotensin Aldosterone Syst; 2014 Sep; 15(3):228-35. PubMed ID: 23223089
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Role of mineralocorticoid receptor on experimental cerebral aneurysms in rats.
    Tada Y; Kitazato KT; Tamura T; Yagi K; Shimada K; Kinouchi T; Satomi J; Nagahiro S
    Hypertension; 2009 Sep; 54(3):552-7. PubMed ID: 19620512
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Preclinical pharmacology of AZD9977: A novel mineralocorticoid receptor modulator separating organ protection from effects on electrolyte excretion.
    Bamberg K; Johansson U; Edman K; William-Olsson L; Myhre S; Gunnarsson A; Geschwindner S; Aagaard A; Björnson Granqvist A; Jaisser F; Huang Y; Granberg KL; Jansson-Löfmark R; Hartleib-Geschwindner J
    PLoS One; 2018; 13(2):e0193380. PubMed ID: 29474466
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mineralocorticoid receptor antagonism induces browning of white adipose tissue through impairment of autophagy and prevents adipocyte dysfunction in high-fat-diet-fed mice.
    Armani A; Cinti F; Marzolla V; Morgan J; Cranston GA; Antelmi A; Carpinelli G; Canese R; Pagotto U; Quarta C; Malorni W; Matarrese P; Marconi M; Fabbri A; Rosano G; Cinti S; Young MJ; Caprio M
    FASEB J; 2014 Aug; 28(8):3745-57. PubMed ID: 24806198
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The selective mineralocorticoid receptor antagonist eplerenone is protective in mild anti-GBM glomeru-lonephritis.
    Zitt E; Eller K; Huber JM; Kirsch AH; Tagwerker A; Mayer G; Rosenkranz AR
    Int J Clin Exp Pathol; 2011 Aug; 4(6):606-15. PubMed ID: 21904636
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacological profile of CS-3150, a novel, highly potent and selective non-steroidal mineralocorticoid receptor antagonist.
    Arai K; Homma T; Morikawa Y; Ubukata N; Tsuruoka H; Aoki K; Ishikawa H; Mizuno M; Sada T
    Eur J Pharmacol; 2015 Aug; 761():226-34. PubMed ID: 26073023
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Angiotensin II- and salt-induced kidney injury through Rac1-mediated mineralocorticoid receptor activation.
    Kawarazaki W; Nagase M; Yoshida S; Takeuchi M; Ishizawa K; Ayuzawa N; Ueda K; Fujita T
    J Am Soc Nephrol; 2012 Jun; 23(6):997-1007. PubMed ID: 22440899
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mineralocorticoid receptor antagonism attenuates cardiac hypertrophy and failure in low-aldosterone hypertensive rats.
    Nagata K; Obata K; Xu J; Ichihara S; Noda A; Kimata H; Kato T; Izawa H; Murohara T; Yokota M
    Hypertension; 2006 Apr; 47(4):656-64. PubMed ID: 16505208
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Eplerenone mimics features of the alternative activation in macrophages obtained from patients with heart failure and healthy volunteers.
    Łabuzek K; Liber S; Bułdak Ł; Krupej-Kędzierska J; Machnik G; Bobrzyk M; Okopień B
    Eur J Pharmacol; 2014 Mar; 726():96-108. PubMed ID: 24486397
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Renoprotective effects of mineralocorticoid receptor blockade in heminephrectomized (pro)renin receptor transgenic rats.
    Mizuguchi Y; Ichihara A; Seki Y; Sakoda M; Kurauchi-Mito A; Narita T; Kinouchi K; Bokuda K; Itoh H
    Clin Exp Pharmacol Physiol; 2010 May; 37(5-6):569-73. PubMed ID: 20082625
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Aldosterone deficiency and mineralocorticoid receptor antagonism prevent angiotensin II-induced cardiac, renal, and vascular injury.
    Luther JM; Luo P; Wang Z; Cohen SE; Kim HS; Fogo AB; Brown NJ
    Kidney Int; 2012 Sep; 82(6):643-51. PubMed ID: 22622494
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Non-genomic effects of spironolactone and eplerenone in cardiomyocytes of neonatal Wistar rats: do they evoke cardioprotective pathways?
    Hermidorff MM; Faria Gde O; Amâncio Gde C; de Assis LV; Isoldi MC
    Biochem Cell Biol; 2015 Feb; 93(1):83-93. PubMed ID: 25488178
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety profile of mineralocorticoid receptor antagonists: Spironolactone and eplerenone.
    Lainscak M; Pelliccia F; Rosano G; Vitale C; Schiariti M; Greco C; Speziale G; Gaudio C
    Int J Cardiol; 2015 Dec; 200():25-9. PubMed ID: 26404748
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mineralocorticoid receptor throughout the vessel: a key to vascular dysfunction in obesity.
    Pojoga LH; Baudrand R; Adler GK
    Eur Heart J; 2013 Dec; 34(45):3475-7. PubMed ID: 23666249
    [No Abstract]   [Full Text] [Related]  

  • 38. Molecular mechanisms of mineralocorticoid receptor antagonism by eplerenone.
    Hu X; Li S; McMahon EG; Lala DS; Rudolph AE
    Mini Rev Med Chem; 2005 Aug; 5(8):709-18. PubMed ID: 16101407
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mineralocorticoid receptor antagonist reduces renal injury in rodent models of types 1 and 2 diabetes mellitus.
    Guo C; Martinez-Vasquez D; Mendez GP; Toniolo MF; Yao TM; Oestreicher EM; Kikuchi T; Lapointe N; Pojoga L; Williams GH; Ricchiuti V; Adler GK
    Endocrinology; 2006 Nov; 147(11):5363-73. PubMed ID: 16901964
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of eplerenone, a selective aldosterone blocker, on blood pressure, serum and macrophage oxidative stress, and atherosclerosis in apolipoprotein E-deficient mice.
    Keidar S; Hayek T; Kaplan M; Pavlotzky E; Hamoud S; Coleman R; Aviram M
    J Cardiovasc Pharmacol; 2003 Jun; 41(6):955-63. PubMed ID: 12775976
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.